OTLC Quote, Financials, Valuation and Earnings

Eli Lilly & Co. has a net margin of -- compared to Oncotelic Therapeutics, Inc.'s net margin of 31.72%. Oncotelic Therapeutics, Inc.'s return on equity of -25.13% beat Eli Lilly & Co.'s return on equity of 106.26%.

Oncotelic Therapeutics, Inc. has a consensus price target of --, signalling upside risk potential of 4164.39%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,056.70 which suggests that it could grow by 4.59%. Given that Oncotelic Therapeutics, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Oncotelic Therapeutics, Inc. is more attractive than Eli Lilly & Co..

Oncotelic Therapeutics, Inc. has a beta of -0.758, which suggesting that the stock is 175.831% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.370, suggesting its less volatile than the S&P 500 by 62.965%.

Oncotelic Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.59% to investors and pays a quarterly dividend of $1.50 per share. Oncotelic Therapeutics, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Oncotelic Therapeutics, Inc. quarterly revenues are --, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Oncotelic Therapeutics, Inc.'s net income of -$1.1M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Oncotelic Therapeutics, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 49.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oncotelic Therapeutics, Inc. is -- versus 15.50x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of -- compared to Oncotelic Therapeutics, Inc.'s net margin of 33.68%. Oncotelic Therapeutics, Inc.'s return on equity of -25.13% beat Merck & Co., Inc.'s return on equity of 39.63%.

Oncotelic Therapeutics, Inc. has a consensus price target of --, signalling upside risk potential of 4164.39%. On the other hand Merck & Co., Inc. has an analysts' consensus of $106.62 which suggests that it could grow by 6.92%. Given that Oncotelic Therapeutics, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Oncotelic Therapeutics, Inc. is more attractive than Merck & Co., Inc..

Oncotelic Therapeutics, Inc. has a beta of -0.758, which suggesting that the stock is 175.831% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.294, suggesting its less volatile than the S&P 500 by 70.604%.

Oncotelic Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 3.25% to investors and pays a quarterly dividend of $0.81 per share. Oncotelic Therapeutics, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Oncotelic Therapeutics, Inc. quarterly revenues are --, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. Oncotelic Therapeutics, Inc.'s net income of -$1.1M is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, Oncotelic Therapeutics, Inc.'s price-to-earnings ratio is -- while Merck & Co., Inc.'s PE ratio is 13.19x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oncotelic Therapeutics, Inc. is -- versus 3.93x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Oncotelic Therapeutics, Inc.'s net margin of -255.85%. Oncotelic Therapeutics, Inc.'s return on equity of -25.13% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Oncotelic Therapeutics, Inc. has a consensus price target of --, signalling upside risk potential of 4164.39%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -29.75%. Given that Oncotelic Therapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Oncotelic Therapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Oncotelic Therapeutics, Inc. has a beta of -0.758, which suggesting that the stock is 175.831% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

Oncotelic Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Oncotelic Therapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Oncotelic Therapeutics, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Oncotelic Therapeutics, Inc.'s net income of -$1.1M is higher than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Oncotelic Therapeutics, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 2.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oncotelic Therapeutics, Inc. is -- versus 2.35x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -- compared to Oncotelic Therapeutics, Inc.'s net margin of 21.32%. Oncotelic Therapeutics, Inc.'s return on equity of -25.13% beat Pfizer Inc.'s return on equity of 10.84%.

Oncotelic Therapeutics, Inc. has a consensus price target of --, signalling upside risk potential of 4164.39%. On the other hand Pfizer Inc. has an analysts' consensus of $29.04 which suggests that it could grow by 11.56%. Given that Oncotelic Therapeutics, Inc. has higher upside potential than Pfizer Inc., analysts believe Oncotelic Therapeutics, Inc. is more attractive than Pfizer Inc..

Oncotelic Therapeutics, Inc. has a beta of -0.758, which suggesting that the stock is 175.831% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.

Oncotelic Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.61% to investors and pays a quarterly dividend of $0.43 per share. Oncotelic Therapeutics, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Oncotelic Therapeutics, Inc. quarterly revenues are --, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Oncotelic Therapeutics, Inc.'s net income of -$1.1M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Oncotelic Therapeutics, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 15.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oncotelic Therapeutics, Inc. is -- versus 2.37x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.